UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of April 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0) 4 30 30 30 (Address of principal executive office) Indicate by check mark whether the registran ...

innate pharma Full Year 2022 Results 23 MARCH 2023 innate pharma Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is inte ...

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President-Business Development and Product Portfolio Strategy Frederic Lombard - Senior Vice President, Chief Financial Officer Conference Call Participants Carly Kenselaar - Citigroup Daina Graybosch - SVB Securit ...

Exhibit 99.1 Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash p ...